Condition: Esophageal Squamous Cell Carcinoma · Neoadjuvant Chemoimmunotherapy · Adjuvant Therapy · Sponsor: Guo Xufeng
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved survival outcomes.
This description comes directly from the study's public registry record.
Xufeng Guo, PH.D · 189-300-96739 · shandagxf@126.com
Xufeng Guo, Ph.D · +8618930096739 · shandagxf@126.com
Always discuss trial participation with your own doctor first.
| Shanghai chest hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06056336